As Novo Nordisk Doubles Down In Obesity And Diabetes, What Exactly Is It Looking For?

Rare Disease Opportunities Still A Focus

 
• By Mandy Jackson
  
Novo intensified its focus on obesity and diabetes after streamlining its operations in September (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from J.P. Morgan

More from Conferences